Sodium stibogluconate cardiotoxicity and safety of generics

被引：29

作者：

Rijal, S

Chappuis, F

Singh, R

Boelaert, M

Loutan, L

Koirala, S

机构：

[1] Univ Hosp Geneva, Travel & Migrat Med Unit, CH-1211 Geneva 14, Switzerland

[2] BP Koirala Inst Hlth Sci, Dharan, Nepal

[3] Inst Trop Med Prince Leopold, Dept Publ Hlth, B-2000 Antwerp, Belgium

来源：

TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE | 2003年 / 97卷 / 05期

关键词：

visceral leishmaniasis; chemotherapy; sodium stibogluconate; generic drugs; cardiotoxicity; Nepal;

D O I：

10.1016/S0035-9203(03)80043-3

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Between April 9 and May 5 2000, an outbreak of fatal cardiotoxicity occurred in Nepal amongst visceral leishmaniasis patients treated with a recently introduced batch of generic sodium stibogluconate (SSG) from GL Pharmaceuticals, Calcutta, India. Eight (36%) of 23 patients treated with this batch died I and in 5 (23%) death was attributed to the cardiotoxicity of the drug. This contrasts with the low total death rate (3.2%) and death rate due to cardiotoxicity (0.8%) observed among 252 patients treated between August 1999 and December 2001 with generic SSG from Albert David Ltd, Calcutta, India. These data show that every batch of generic SSG should be subject to rigorous quality control prior to use.

引用

页码：597 / 598

页数：2

共 8 条

[1]

BERMAN JD, 1988, REV INFECT DIS, V10, P560

[2]

CHAKRABORTY A, 2000, STATESMAN 0610, P1

[3]

CHAKRABORTY A, 2000, STATESMAN 0610, P5

[4]

Moore E, 2001, B WORLD HEALTH ORGAN, V79, P388